Skip to main content
Top
Published in: Digestive Diseases and Sciences 7/2016

01-07-2016 | Fellows and Young Gis Section

Why Pursue a Fourth Year in Advanced/Transplant Hepatology?

Authors: Arpan Mohanty, Brett E. Fortune

Published in: Digestive Diseases and Sciences | Issue 7/2016

Login to get access

Excerpt

The traditional pathway for advanced/transplant hepatology training consists of a 1-year fellowship program, accredited by the Accreditation Council for Graduate Medical Education (ACGME), and is usually completed after finishing a 3-year gastroenterology fellowship—thus referred to as a “fourth year.” However, in hopes to increase the number of trained transplant hepatologists given the growing job demand, the American Board of Internal Medicine (ABIM) and American Association for the Study of Liver Diseases (AASLD) have developed a collaborative pilot program, which combines training in gastroenterology and advanced/transplant hepatology within a 3-year timeline at selected institutions [1]. So far, 31 fellows (14 fellows for the current academic year 2015–2016) have enrolled in the program. Interval data evaluating the early metrics of the pilot program are not yet available. This article will focus on the potential strengths in pursuing a fourth year of training in advanced/transplant hepatology as well as the potential pitfalls of the combined pilot program. …
Literature
1.
go back to reference Rustgi VK, Davis GL, Herrine SK, et al. Future trends in hepatology: challenges and opportunities. Hepatology. 2008;48:655–661.CrossRefPubMed Rustgi VK, Davis GL, Herrine SK, et al. Future trends in hepatology: challenges and opportunities. Hepatology. 2008;48:655–661.CrossRefPubMed
2.
go back to reference Kim Y, Ejaz A, Tayal A, et al. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer. 2014;120:3058–3065.CrossRefPubMedPubMedCentral Kim Y, Ejaz A, Tayal A, et al. Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years. Cancer. 2014;120:3058–3065.CrossRefPubMedPubMedCentral
3.
4.
go back to reference Chhatwal J, Wang X, Kanwal F, et al. Hepatitis C disease burden in the United States in 2015 and beyond. Hepatology. 2015;62:33A–92A.CrossRef Chhatwal J, Wang X, Kanwal F, et al. Hepatitis C disease burden in the United States in 2015 and beyond. Hepatology. 2015;62:33A–92A.CrossRef
5.
go back to reference Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.CrossRefPubMed Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274–285.CrossRefPubMed
6.
go back to reference Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.CrossRefPubMed Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124–131.CrossRefPubMed
Metadata
Title
Why Pursue a Fourth Year in Advanced/Transplant Hepatology?
Authors
Arpan Mohanty
Brett E. Fortune
Publication date
01-07-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 7/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-016-4108-3

Other articles of this Issue 7/2016

Digestive Diseases and Sciences 7/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.